Patient-, disease- and treatment-related characteristics of patients with AML receiving HLA–identical sibling bone marrow transplantation in first complete remission
| . | (1) No postremission therapy . | (2) Standard-dose cytarabine . | (3) High-dose cytarabine . | P12 . | P13 . | P23 . |
|---|---|---|---|---|---|---|
| Number of patients | 62 | 222 | 147 | |||
| Median age, years | 32 (2-55) | 29 (<1-56) | 28 (1-52) | 0.34 | 0.24 | 0.37 |
| Male sex, n (%) | 33 (53) | 112 (50) | 79 (54) | 0.70 | 0.95 | 0.54 |
| Performance score ≥ 90%, n (%) | 54 (87) | 196 (88) | 132 (90) | 0.80 | 0.57 | 0.65 |
| Cytomegalovirus seropositive, n (%) | 37 (60) | 128 (59) | 100 (68) | 0.95 | 0.22 | 0.07 |
| FAB subtype, n (%) | 0.02 | <0.001 | 0.53 | |||
| Unclassified | 7 (11) | 9 (4) | 2 (1) | |||
| M1, M2 | 35 (57) | 98 (44) | 61 (42) | |||
| M3 | 7 (11) | 26 (12) | 18 (12) | |||
| M4 | 6 (10) | 53 (24) | 36 (25) | |||
| M5-M7 | 7 (11) | 36 (16) | 30 (20) | |||
| Median leukocytes at diagnosis, ×109/L | 7 (1-400) | 17 (1-409) | 14 (1-510) | 0.02 | 0.02 | 0.94 |
| Cytogenetics, n (%) | 0.47 | 0.90 | 0.02 | |||
| Normal | 16 (33) | 51 (27) | 43 (35) | |||
| Good prognosis | 9 (19) | 28 (15) | 18 (14) | |||
| Intermediate prognosis | 7 (15) | 21 (11) | 22 (18) | |||
| Poor prognosis | 1 (2) | 3 (1) | 5 (4) | |||
| Unknown | 15 (31) | 89 (46) | 36 (29) | |||
| Extramedullary disease at DX, n (%) | 3 (5) | 30 (14) | 20 (14) | 0.06 | 0.07 | 0.99 |
| Additional drugs for consolidation | — | 218 (98) | 113 (77) | — | — | <0.001 |
| No. cycles to achieve CR, n (%) | 0.01 | 0.24 | 0.09 | |||
| 1 | 33 (53) | 156 (70) | 91 (62) | |||
| 2 | 29 (47) | 66 (30) | 56 (38) | |||
| Median time from DX to CR, mo | 1.3 (0.2-13.7) | 1.0 (0.2-12.8) | 1.3 (0.4-5.6) | 0.72 | 0.70 | 0.99 |
| Median time from CR to transplantation, mo | 2.2 (0.5-15.1) | 4.2 (0.2-26.3) | 5.1 (0.4-16.9) | <0.001 | <0.001 | 0.004 |
| TBI for conditioning, n (%) | 22 (35) | 120 (54) | 88 (60) | 0.01 | <0.001 | 0.27 |
| GVHD prophylaxis, n (%) | <0.001 | 0.05 | 0.05 | |||
| CsA + MTX | 29 (47) | 142 (64) | 80 (54) | |||
| CsA or MTX | 24 (39) | 32 (14) | 35 (24) | |||
| Other | 3 (5) | 1 (<1) | 3 (2) | |||
| T-depletion | 6 (9) | 47 (21) | 29 (20) | |||
| Year of transplantation | 0.72 | 0.08 | 0.04 | |||
| 1989-1991 | 39 (63) | 134 (60) | 73 (50) | |||
| 1992-1995 | 23 (37) | 88 (40) | 74 (50) | |||
| Median follow-up time, mo | 60 | 61 | 61 | 0.22* | 0.10* | 0.44* |
| . | (1) No postremission therapy . | (2) Standard-dose cytarabine . | (3) High-dose cytarabine . | P12 . | P13 . | P23 . |
|---|---|---|---|---|---|---|
| Number of patients | 62 | 222 | 147 | |||
| Median age, years | 32 (2-55) | 29 (<1-56) | 28 (1-52) | 0.34 | 0.24 | 0.37 |
| Male sex, n (%) | 33 (53) | 112 (50) | 79 (54) | 0.70 | 0.95 | 0.54 |
| Performance score ≥ 90%, n (%) | 54 (87) | 196 (88) | 132 (90) | 0.80 | 0.57 | 0.65 |
| Cytomegalovirus seropositive, n (%) | 37 (60) | 128 (59) | 100 (68) | 0.95 | 0.22 | 0.07 |
| FAB subtype, n (%) | 0.02 | <0.001 | 0.53 | |||
| Unclassified | 7 (11) | 9 (4) | 2 (1) | |||
| M1, M2 | 35 (57) | 98 (44) | 61 (42) | |||
| M3 | 7 (11) | 26 (12) | 18 (12) | |||
| M4 | 6 (10) | 53 (24) | 36 (25) | |||
| M5-M7 | 7 (11) | 36 (16) | 30 (20) | |||
| Median leukocytes at diagnosis, ×109/L | 7 (1-400) | 17 (1-409) | 14 (1-510) | 0.02 | 0.02 | 0.94 |
| Cytogenetics, n (%) | 0.47 | 0.90 | 0.02 | |||
| Normal | 16 (33) | 51 (27) | 43 (35) | |||
| Good prognosis | 9 (19) | 28 (15) | 18 (14) | |||
| Intermediate prognosis | 7 (15) | 21 (11) | 22 (18) | |||
| Poor prognosis | 1 (2) | 3 (1) | 5 (4) | |||
| Unknown | 15 (31) | 89 (46) | 36 (29) | |||
| Extramedullary disease at DX, n (%) | 3 (5) | 30 (14) | 20 (14) | 0.06 | 0.07 | 0.99 |
| Additional drugs for consolidation | — | 218 (98) | 113 (77) | — | — | <0.001 |
| No. cycles to achieve CR, n (%) | 0.01 | 0.24 | 0.09 | |||
| 1 | 33 (53) | 156 (70) | 91 (62) | |||
| 2 | 29 (47) | 66 (30) | 56 (38) | |||
| Median time from DX to CR, mo | 1.3 (0.2-13.7) | 1.0 (0.2-12.8) | 1.3 (0.4-5.6) | 0.72 | 0.70 | 0.99 |
| Median time from CR to transplantation, mo | 2.2 (0.5-15.1) | 4.2 (0.2-26.3) | 5.1 (0.4-16.9) | <0.001 | <0.001 | 0.004 |
| TBI for conditioning, n (%) | 22 (35) | 120 (54) | 88 (60) | 0.01 | <0.001 | 0.27 |
| GVHD prophylaxis, n (%) | <0.001 | 0.05 | 0.05 | |||
| CsA + MTX | 29 (47) | 142 (64) | 80 (54) | |||
| CsA or MTX | 24 (39) | 32 (14) | 35 (24) | |||
| Other | 3 (5) | 1 (<1) | 3 (2) | |||
| T-depletion | 6 (9) | 47 (21) | 29 (20) | |||
| Year of transplantation | 0.72 | 0.08 | 0.04 | |||
| 1989-1991 | 39 (63) | 134 (60) | 73 (50) | |||
| 1992-1995 | 23 (37) | 88 (40) | 74 (50) | |||
| Median follow-up time, mo | 60 | 61 | 61 | 0.22* | 0.10* | 0.44* |
CMV, cytomegalovirus; FAB, French-American-British; DX, diagnosis; CR, complete remission; TBI, total body irradiation; GVHD, graft-versus-host disease; CsA, cyclosporine; MTX, methotrexate.
P12, probability of testing (1) = (2).
P13, probability of testing (1) = (3).
P23, probability of testing (2) = (3).
Log-rank test.